Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

Gut. 2021 Oct;70(10):2020-2022. doi: 10.1136/gutjnl-2021-324397. Epub 2021 Mar 3.

Authors

Mohamed Attauabi^{1

2

3}, Jakob Seidelin³, Johan Burisch^{4

2}; Danish COVID-IBD Study Group

Collaborators

Affiliations

¹ Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark attauabi12@gmail.com.
² Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Copenhagen, Denmark.
³ Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
⁴ Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark.

PMID: 33658323
DOI: 10.1136/gutjnl-2021-324397

No abstract available

Keywords: 5-aminosalicylic acid (5-ASA); COVID-19; crohn's disease; inflammatory bowel disease; ulcerative colitis.

Publication types

Letter
Comment

MeSH terms

COVID-19*
Colitis, Ulcerative* / drug therapy
Humans
Mesalamine
Research Design
SARS-CoV-2

Substances

Mesalamine